Prime Biome has mainly received positive reviews, with users reporting skin clarity, digestion, and overall well-being ...
Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that the United States (U.S.) Food ...
Clene planning to submit a New Drug Application (NDA) in the second half of 2025 for potential Accelerated Approval of CNM-Au8® in ALSClene ...
MLB is back, as the Los Angeles Dodgers officially opened up the 2025 regular season with a 4–1 win over the Chicago Cubs in Tokyo. And MLB fans might notice—or may have already noticed—one new aspect ...
Join the FDA Inspection Preparedness & Compliance Online Training (May 7-8, 2025) to master regulatory inspection readiness for pharma, biotech, biologics, and medical device industries. This ...
Hubble Therapeutics LLC a patient-focused biotechnology company developing a gene therapy to cure pediatric blindness, announces the successful ...
Global Cosmetics ODM (Original Development Manufacturer) Kolmar Korea has achieved a groundbreaking milestone by developing ...
The FDA wants bulk production of copycat versions of popular weight-loss drugs to stop, but telehealth companies and compounding pharmacies that have fueled widespread use of the knockoffs have ...
If the FDA is happy with daprodustat's safety profile and approves the drug, it will help GSK meet its target of £500 million to £1 billion ($650 million to $1.3 billion) in sales for the drug ...
DelveInsight's "EMPAVELI Market Size, Forecast, and Market Insight Report" highlights the details around EMPAVELI, a ...
“We don’t have a lot of information to share but we believe that the FDA has performed similar actions towards other companies recently,” read a statement shared on the Double Scorpio website ...
2-Year U.S. Treasury Note Continuous Contract $103.547 0.012 0.01% 5-Year U.S. Treasury Note Continuous Contract $108.031 0.016 0.01% 10-Year U.S. Treasury Note Continuous Contract $111.141-0.031 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results